(R)-methyl 2-(8-bromo-7-nitrodibenzo[b,d]furan-2-sulfonamido)-3-methylbutanoate | 1025719-89-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并呋喃
• 英文名称: (R)-methyl 2-(8-bromo-7-nitrodibenzo[b,d]furan-2-sulfonamido)-3-methylbutanoate
• CAS: 1025719-89-4
• 化学式: C₁₈H₁₇BrN₂O₇S
• 分子量: 485.312
• InChiKey: VCCHUEDOEXNQDH-QGZVFWFLSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.73
• 重原子数：
  29.0
• 可旋转键数：
  6.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.28
• 拓扑面积：
  128.75
• 氢给体数：
  1.0
• 氢受体数：
  7.0

反应信息

• 作为反应物：
  描述：

  (R)-methyl 2-(8-bromo-7-nitrodibenzo[b,d]furan-2-sulfonamido)-3-methylbutanoate 在 tin(ll) chloride 作用下， 以 乙酸乙酯 为溶剂， 以88%的产率得到(R)-methyl 2-(8-bromo-7-aminodibenzo[b,d]furan-2-sulfonamido)-3-methylbutanoate
  参考文献：
  名称：

  A Selective Matrix Metalloprotease 12 Inhibitor for Potential Treatment of Chronic Obstructive Pulmonary Disease (COPD): Discovery of (S)-2-(8-(Methoxycarbonylamino)dibenzo[b,d]furan-3-sulfonamido)-3-methylbutanoic acid (MMP408)

  摘要：

  Matrix metalloprotease 12 plays a significant role in airway inflammation and remodeling. Increased expression and production of MMP-12 have-been found in the lung of human COPD patients. MMP408 (14), a potent and selective MMP-12 inhibitor, was derived from a potent matrix metalloprotease 2 and 13 inhibitor via lead optimization and has good physical properties and bioavailability. The compound blocks rhMMP-12-induced lung inflammation in a mouse model and was advanced for further development for the treatment of COPD.

  DOI：

  10.1021/jm900093d
• 作为产物：
  描述：

  8-溴-7-硝基二苯并[b,d]呋喃-2-磺酰氯 、 D-缬氨酸甲酯盐酸盐 在 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 为溶剂， 以95%的产率得到(R)-methyl 2-(8-bromo-7-nitrodibenzo[b,d]furan-2-sulfonamido)-3-methylbutanoate
  参考文献：
  名称：

  A Selective Matrix Metalloprotease 12 Inhibitor for Potential Treatment of Chronic Obstructive Pulmonary Disease (COPD): Discovery of (S)-2-(8-(Methoxycarbonylamino)dibenzo[b,d]furan-3-sulfonamido)-3-methylbutanoic acid (MMP408)

  摘要：

  Matrix metalloprotease 12 plays a significant role in airway inflammation and remodeling. Increased expression and production of MMP-12 have-been found in the lung of human COPD patients. MMP408 (14), a potent and selective MMP-12 inhibitor, was derived from a potent matrix metalloprotease 2 and 13 inhibitor via lead optimization and has good physical properties and bioavailability. The compound blocks rhMMP-12-induced lung inflammation in a mouse model and was advanced for further development for the treatment of COPD.

  DOI：

  10.1021/jm900093d

文献信息

• WO2008/57254
  申请人：——

  公开号：——

  公开（公告）日：——